• Explore /
  • Poster
  • / Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.

Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.

Abstract Video & Slides Poster

Authors

null

Jonathan E. Rosenberg

Memorial Sloan Kettering Cancer, New York, NY

Jonathan E. Rosenberg , Thomas W. Flaig , Terence W. Friedlander , Matthew I. Milowsky , Sandy Srinivas , Daniel Peter Petrylak , Jaime R. Merchan , Mehmet Asim Bilen , Anne-Sophie Carret , Nancy Yuan , Carolyn Sasse , Christopher J. Hoimes

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Bladder Cancer

Clinical Trial Registration Number

NCT03288545

Citation

J Clin Oncol 38: 2020 (suppl; abstr 5044)

DOI

10.1200/JCO.2020.38.15_suppl.5044

Abstract #

5044

Poster Bd #

113

Abstract Disclosures

Similar Posters

First Author: Nataliya Mar

First Author: Jonathan E. Rosenberg

First Author: Peter H. O'Donnell

First Author: Terence W. Friedlander